Monitor upcoming quarterly filings for initial prescription volumes and revenue contribution from IMPAVIDO. The launch leverages Eton's existing rare disease infrastructure, which may improve operating leverage if the product gains traction.
Price Chart
Executive Summary
Eton Pharmaceuticals announced the U.S. commercial launch of IMPAVIDO (miltefosine) capsules, a treatment for leishmaniasis, with exclusive U.S. commercialization rights. The company has integrated patient support programs and centralized distribution through Anovo Specialty Pharmacy. This is a product relaunch into Eton's rare disease infrastructure, adding to its existing portfolio of eleven commercial rare disease products.
Key Facts
- Eton launched IMPAVIDO (miltefosine) capsules in the U.S. on September 28, 2026.
- Eton holds exclusive commercialization rights for IMPAVIDO in the United States.
- Distribution is centralized through Anovo Specialty Pharmacy with patient support programs including $0 co-pay for eligible commercially insured patients.
- IMPAVIDO is indicated for visceral, cutaneous, and mucosal leishmaniasis in adults and adolescents 12 years of age weighing at least 30 kg.
- Eton now has eleven commercial rare disease products; IMPAVIDO is the eighth named commercial product in the press release.
Financial Impact
No financial figures provided in the filing. The launch adds a new revenue stream from an existing approved drug, but revenue contribution is undisclosed.
Risk Factors
- Leishmaniasis is a rare disease with a small patient population, limiting peak revenue potential.
- Competition from CDC stockpiles or other miltefosine suppliers could limit market share.
- No revenue or guidance was provided in this filing, so the financial impact is uncertain.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-031281 |
| Exhibit: ex_1019083.htm | 0001437749-26-031281 |
| Document: 0001437749-26-031281-index-headers.html | 0001437749-26-031281 |
| Document: 0001437749-26-031281-index.html | 0001437749-26-031281 |
| Document: 0001437749-26-031281.txt | 0001437749-26-031281 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | 8-K | $52.88 | awaiting T+60 | — | $51.16 (−3.25%) |
Oct 6, 2026 21d ago | 144 | $54.88 | awaiting T+60 | — | $51.16 (−6.78%) |
Sep 28, 2026 29d ago | 8-K | $59.18 | awaiting T+60 | — | $51.16 (−13.55%) |
Aug 31, 2026 8w ago | Insider Cluster | $60.43 | awaiting T+60 | — | $51.16 (−15.34%) |
Aug 28, 2026 8w ago | Insider Cluster | $60.44 | awaiting T+60 | — | $51.16 (−15.35%) |
Aug 24, 2026 9w ago | Insider Cluster | $63.05 | awaiting T+60 | — | $51.16 (+18.86%) |
Aug 19, 2026 9w ago | 144 | $61.48 | awaiting T+60 | — | $51.16 (+16.79%) |
Aug 5, 2026 11w ago | 8-K | $45.97 | awaiting T+60 | — | $51.16 (+11.29%) |
Aug 5, 2026 11w ago | Press Release | $45.97 | awaiting T+60 | — | $51.16 (+11.29%) |
Aug 4, 2026 12w ago | 8-K | $45.83 | awaiting T+60 | — | $51.16 (+11.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers